Stephen Bradley

Stephen Bradley is an enthusiastic and driven bioanalytical leader specializing in Clinical and Bioanalytical sciences, with extensive experience across multiple therapeutic areas, including Rare Diseases, Oncology, and Immunology. They have held notable positions at companies such as Apellis Pharmaceuticals, where they developed a comprehensive Immunogenicity platform, and Novartis Institutes for BioMedical Research, managing teams focused on PK and Biomarker assay development. Currently, Stephen serves as a Senior Director at Solid Biosciences while also advising on immunogenicity strategy and execution. They earned a Master of Science in Biotechnology Pharmaceutical Science from Northeastern University.